Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 -0.68%87 Return-on-Tangible-Equity is 9.60% as of Mar. 2026, which is 76% below its 10-year median of 40.28. GuruFocus rates BSP:BLAU3 with a GF Score™ of 87/100 and a GF Value™ of R$11.18 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 900 Drug Manufacturers companies, Blau Farmaceutica ranks better than 68.78% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Blau Farmaceutica's annualized net income for the quarter that ended in Mar. 2026 was R$159 Mil. Blau Farmaceutica's average shareholder tangible equity for the quarter that ended in Mar. 2026 was R$1,657 Mil. Therefore, Blau Farmaceutica's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 9.60%.
The historical rank and industry rank for Blau Farmaceutica's Return-on-Tangible-Equity or its related term are showing as below:
BSP:BLAU3'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 13.07 Med: 40.28 Max: 171.87
Current: 14.33
During the past 10 years, Blau Farmaceutica's highest Return-on-Tangible-Equity was 171.87%. The lowest was 13.07%. And the median was 40.28%.
BSP:BLAU3's Return-on-Tangible-Equity is ranked better than 68.78% of 900
companies
in the Drug Manufacturers industry
Industry Median: 7.895
vs BSP:BLAU3: 14.33
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Blau Farmaceutica Return-on-Tangible-Equity Related Terms
Blau Farmaceutica Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 9.60% mean?
Blau Farmaceutica (BSP:BLAU3) has a Return-on-Tangible-Equity of 9.60% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Blau Farmaceutica and its competitors. This is 76% below median its historical median of 40.28. Over the past decade, Blau Farmaceutica's Return-on-Tangible-Equity has ranged from 13.07 to 171.87. According to the industry distribution chart, Blau Farmaceutica ranks #281 out of 900 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Blau Farmaceutica's Return-on-Tangible-Equity too high?
Blau Farmaceutica's current Return-on-Tangible-Equity of 9.60% is 76% below median its 10-year median of 40.28. Over the past 10 years, this metric has ranged from a low of 13.07 to a high of 171.87. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Blau Farmaceutica's value of 9.60% is 21.6% above this industry median. Based on the distribution chart, Blau Farmaceutica ranks #281 out of 900 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Blau Farmaceutica has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #281 out of 900 companies for Return-on-Tangible-Equity. This puts Blau Farmaceutica in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Blau Farmaceutica's value of 9.60% is 21.6% above this benchmark. Historically, Blau Farmaceutica's own Return-on-Tangible-Equity has ranged from 13.07 to 171.87 over the past decade. While the company's 10-year median is 40.28 vs. the industry median of 7.90, Blau Farmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current Return-on-Tangible-Equity of 9.60% is 21.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current Return-on-Tangible-Equity is 9.60%, which is 76% below median its own 10-year median of 40.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$11.18, compared to a current price of R$8.71 — trading 22.1% below its estimated fair value. The current Return-on-Tangible-Equity is 9.60%, which is 76% below median its 10-year median of 40.28 and 21.6% above the Drug Manufacturers industry median of 7.90. Blau Farmaceutica's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current Return-on-Tangible-Equity is 9.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$8.71 is trading 22.1% below its estimated GF Value™ of R$11.18.
GuruFocus considers Blau Farmaceutica to be Modestly Undervalued.
Key valuation signals for BSP:BLAU3:
Return-on-Tangible-Equity: 9.60% (76% below median its 10-year median of 40.28)
GF Value™: R$11.18 vs. price of R$8.71 (22.1% below fair value)
Industry Position: 21.6% above the Drug Manufacturers median (#281 of 900)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
87GF Score
Get the complete analysis for BSP:BLAU3
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
